NeoGenomics Unveils PanTracer Pro with 500-Gene Profiling and 8-10 Day Turnaround
NeoGenomics launched PanTracer Pro, a pan-solid tumor assay combining DNA/RNA sequencing of over 500 genes with IHC ancillary testing, reducing diagnostic complexity and delivering results in 8–10 days. In FY2025 the company reported $727 million in sales, up 10% year over year, and expects double-digit growth in 2026.
1. Launch of PanTracer Pro
NeoGenomics introduced PanTracer Pro, a pan-solid tumor assay integrating broad DNA and RNA sequencing across more than 500 cancer-related genes with targeted immunohistochemistry and ancillary tests. The platform streamlines diagnostic workflows into a single coordinated order and delivers results within 8–10 days to support faster treatment planning.
2. FY2025 Financial Performance
In full-year 2025 NeoGenomics posted preliminary sales of $727 million, marking a 10% increase year over year and extending a 36.6% revenue rise since 2021. Following the launch announcement, shares climbed 1.9%, contributing to an 82.4% gain over the past six months versus industry growth of 21.6%.
3. 2026 Growth Outlook
Management anticipates sustained double-digit revenue growth in 2026, driven by the expanded oncology test menu, including PanTracer Pro’s comprehensive genomic profiling and liquid biopsy options. The company expects the new assay to enhance market adoption and support ongoing top-line momentum in precision oncology services.